"Many of these patients will not take advantage of the program, as they don't now with Pfizer's current Share Card program, " noted Winton Gibbons, a stock analyst at William Blair.
But in a note to investors this morning, Winton Gibbons, a health care analyst at William Blair, said he believes the probe probably relates to doctors using Rituxan for so-called off-label uses.